NCT00969449已完成1 期
An Open Label, Randomized, Two-Way Crossover Trial to Compare the Pharmacokinetic Parameters of an Extended- Release Naproxen Sodium Tablet Relative to Naprelan® Tablets Following Single Dose Administration Under Fasted Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 28
- 主要终点
- Pharmacokinetic profile of Naproxen Sodium ER 660 mg compared to Naprelan
研究概览
简要总结
To compare the pharmacokinetic profile of the proposed extended- release tablet of naproxen sodium 660 mg relative to two tablets of Naprelan 500 mg following single dose administration for 36 hours under fasted conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female subjects between 18 to 55 years of age inclusive with a Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs)
- •Results of screening and clinical laboratory tests are within normal range or considered not clinically significant by the Principal Investigator or Sponsor
- •Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera®, or a double barrier and have a negative pregnancy test at Screening and Day 0 for each Dosing Period. Female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy
- •Be willing to participate in all scheduled visits, treatment plan, laboratory tests and other trial procedures according to the clinical protocol
排除标准
- •History of hypersensitivity to aspirin (ASA), naproxen sodium, or acetaminophen, and similar pharmacological agents or components of the products
- •Females who are pregnant or lactating
- •Loss of blood in excess of 500 ml within 56 days of the first dose of trial treatment (e.g., donation, plasmapheresis or injury)
- •History of gastrointestinal bleeding or perforation, related to previous NSAID therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding)
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases or malignancies
- •Positive alcohol or drug test at Screening and on Day 0 of each Dosing Period
- •Have taken any medications (except acceptable forms of birth control) within 10 days prior to dosing or throughout the trial, unless in the opinion of the Investigator and the Sponsor, the medication will not interfere with the trial procedures, data integrity, or compromise the safety of the subject
- •Have taken ASA, ASA-containing products, acetaminophen (acetyl-para-amino-phenol or APAP) or any NSAID (OTC or prescription) 7 days prior to dosing or during the treatment period, other than trial treatment
研究组 & 干预措施
Arm 1
Experimental
干预措施: Naproxen Sodium, (BAY H6689) (Drug)
Arm 2
Active Comparator
干预措施: Naprelan, (BAY H6689) (Drug)
结局指标
主要结局
Pharmacokinetic profile of Naproxen Sodium ER 660 mg compared to Naprelan
时间窗: 36 hours
次要结局
- To assess safety and tolerability of the extended release naproxen sodium(36 hours)
- To assess additional pharmacokinetic parameters(36 hours)
研究者
相似试验
已完成
1 期
Single/Multiple Dose Bioavailability TrialHealthyNCT00751556Bayer32
已完成
3 期
Evaluate Efficacy and Safety of Extended Release (ER) Naproxen SodiumPain, PostoperativeNCT01389284Bayer300
已完成
3 期
Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.ToothacheNCT00720057Bayer312
已完成
1 期
Study Evaluating the Bioavailability of Naproxen 500 mg in Three FormulationsArthritisNCT00665743POZEN30
已完成
1 期
A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma LevelsArthritisNCT00749385POZEN40